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of detection than what should be attain-
able.[3] This is mainly because of rapid 
molecular tumbling (τR < 100 ps) and low 
hydration states (q = 1). Low r1 values limit 
the use of small molecule Gd(III) che-
lates in targeted imaging because a large 
local concentration of the CAs is needed 
to produce a detectable change in R1. To 
overcome this limit of sensitivity, different 
strategies have been explored. The most 
common strategy involves the preparation 
of nanoscale or macromolecular formula-
tions in which multiple Gd(III) chelates 
are associated.[4] Since r1 is linearly pro-
portional to the concentration of the CA, 
a high payload (>> 100 ions) is critical to 
attain a high local concentration at the 
biological target site; that is, for each tar-
geting event of the macromolecule or 
particle species, multiple Gd(III) centers 
are localized. Ideally then, these systems would possess high 
molecular r1 resulting from the combined effect of the large 
number of Gd(III) ions and the slow global rotational motion 
that increases r1 of each individual Gd-complex.[5] Noncovalently 
bound MRI CAs often suffer from weak associations limiting 
applications in vivo. In one example, protein engineering has 
enabled the design of Gd-specific binding proteins that show 
excellent metal selectivity and stability.[6] However, the sophisti-
cated preparation processes prevent large-scale production with 
immunogenicity also being a concern. Covalently linking small 
molecule chelates with synthetic polymers or nanoparticles 
This study reports the preparation of a series of gadolinium-polydopamine 
nanoparticles (GdPD-NPs) with tunable metal loadings. GdPD-NPs are ana-
lyzed by nuclear magnetic relaxation dispersion and with a 7-tesla (T) mag-
netic resonance imaging (MRI) scanner. A relaxivity of 75 and 10.3 mM−1 s−1 
at 1.4 and 7 T is observed, respectively. Furthermore, superconducting 
quantum interference device magnetometry is used to study intraparticle 
magnetic interactions and determine the GdPD-NPs consist of isolated metal 
ions even at maximum metal loadings. From these data, it is concluded that 
the observed high relaxivities arise from a high hydration state of the Gd(III) 
at the particle surface, fast rate of water exchange, and negligible antifer-
romagnetic coupling between Gd(III) centers throughout the particles. This 
study highlights design parameters and a robust synthetic approach that 
aid in the development of this scaffold for T1-weighted, high relaxivity MRI 
contrast agents.
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Contrast media are used in a third of the ≈80 million mag-
netic resonance imaging (MRI) exams performed worldwide 
each year.[1] Those approved for clinical use are low molecular 
weight, paramagnetic, Gd(III) chelates. They increase the 
signal intensity on T1-weighted images, shorten the examina-
tion time, improve the diagnostic confidence, and enhance 
the image contrast.[2] Relaxivity, r1, is an important parameter 
that measures the ability of a Gd-complex to change R1 (1/T1) 
of nearby water protons. Currently used Gd-based contrast 
agents (CAs) exhibit only a fraction of the efficacy (r1) pre-
dicted by theoretical models translating to a lower sensitivity 
Small 2017, 13, 1701830
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often results in r1 values that are lower than theory would sug-
gest based on the tumbling rates of the macromolecule or par-
ticle. The major limiting factors in many of these formulations 
have been the relatively slow rate of exchange of the bound 
water (kex = 1/τM) and the occurrence of fast, local rotational 
motion of the Gd(III)-complex about the linker that connects it 
to the nanoparticle.[5]
The strong metal binding ability of catechol-based functional 
groups has led to an interest in polydopamine (PD)-based nan-
oparticles (PD-NPs) in a growing number of research areas, 
including bioimaging,[7] battery materials,[8] catalysis,[9] and 
environmental remediation.[10] In addition, PD-NPs and natu-
rally occurring melanin-based nanoparticles doped with Fe(III) 
and Mn(II) have been reported as MRI contrast agents.[11] 
Recently, a prepolymerization doping strategy was reported 
to prepare Fe(III)-loaded PD-NPs in a single pot.[12] However, 
adapting this procedure to synthesize high and tunable Gd(III)-
content PD-NPs has remained a challenge.[13] In addition, pre-
vious strategies do not result in ultrahigh relaxivity, and we 
expect to generate high relaxivity close to the theoretic limit.[13c] 
Unlike transition metals such as Zn(II), Fe(III), and Mn(III), 
the methodology of introducing metal salts during the polymer-
ization of dopamine is not compatible for the incorporation of 
the Gd(III) ion. Therefore, we developed a metal displacement 
method for the synthesis of a series of Gd(III)-polydopamine 
nanoparticles (GdPD-NPs) with variable Gd loadings, allowing 
an investigation of the basic properties of these materials in 
the context of their MRI contrast agents’ performance. Given 
the high coordination number of Gd(III)-complexes, fast H2O 
exchange, weak antiferromagnetic superexchange interactions, 
and strong anchoring chelation provided by the PDA catechol 
moiety, we expect to generate high relaxivity close to the theo-
retic limit.
We first prepared GdPD-NPs using a postparticle forma-
tion doping strategy (Figure 1). PD-NPs were synthesized via 
auto-oxidation and polymerization of dopamine under basic 
conditions.[14] The resulting nanoparticles were characterized 
by transmission electron microscopy (TEM) and dynamic light 
scattering (DLS) to quantify size and uniformity (Figures S1 
and S2, Supporting Information). TEM shows spherical parti-
cles with diameters of ≈160 nm. After complexation with Gd, 
the morphology remains unchanged (Figure S1, Supporting 
Information). This is consistent with previous studies on iron-
loaded polydopamine nanoparticles (FePD-NPs). Inductively 
coupled plasma atomic emission spectroscopy (ICP-OES) 
analysis was used to determine the Gd loadings to be 2 wt% 
(massGd/massGdPD-NP). Though this postparticle formation 
doping strategy was successfully applied to prepare GdPD-NPs, 
the approach is limited to low Gd loading. Regardless Gd(III) 
could not be incorporated via the prepolymerization doping 
route as described in previous sections. This route does not 
produce uniform nanoparticles (Figure S3, Supporting Infor-
mation). Additionally, the resulting nanoaggregates are col-
loidally unstable after polymerization and thus unsuitable for 
the analysis of their MRI performance. Therefore, we devised 
a strategy to first synthesize MnPD-NPs with controllable 
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Figure 1. Preparation of GdPD-NPs (Gd-i (i = 1–5)): a) Postparticle formation doping strategy used to generate Gd-1. b) The prepolymerization doping 
strategy used to generate particles Gd-2, Gd-3, Gd-4, and Gd-5. White and red dots represent Gd(III) and Mn(III) ions, respectively. c) TEM micrograph 
of Mn(III)-doped PD-NPs (Mn-4) and d) corresponding GdPD-NPs (Gd-4). Gd loadings for Gd-1, Gd-2, Gd-3, Gd-4, and Gd-5 are 2%, 3%, 5%, 11%, 
and 17%, respectively.
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Mn(III) loadings. These structures served as templates with 
Mn(III) binding sites primed for displacement when treated 
with GdCl3. MnPD-NPs were prepared through the oxidative 
polymerization of dopamine in the presence of Mn(III) salts 
under basic conditions as previously reported.[15a] We initially 
observe a red solution suggesting the formation of an Mn(III)-
catecholate species,[15b] which is polymerized to form black 
MnPD-NPs. The incorporation of Mn can be confirmed by 
X-ray photoelectron spectroscopy (XPS). As shown in Figure S4 
(Supporting Information), the XPS spectrum of MnPD-NPs 
showed a typical binding energy (641.7 eV) at the charac-
teristic peak of Mn(2p3/2), which can be assigned to Mn(III). 
Recent magnetometry studies on materials prepared via this 
method for MnPD-NPs have corroborated the trivalent oxida-
tion state, likely due to the highly oxidative conditions of the 
polymerization.[15a]
After work-up and isolation of the MnPD-NPs, a simple 
ion exchange procedure was attempted. MnPD-NPs were sus-
pended in an aqueous solution of excess GdCl3 and incubated 
for ≈12 h. The extent of the displacement reaction was deter-
mined by the analysis of XPS and ICP-OES data before and 
after the Gd(III) incubation. As shown in Figure S4 (Supporting 
Information), the initial survey scan spectrum of MnPD-NPs 
exhibits binding energies at the characteristic peaks of C(1s), 
O(1s), N(1s), and Mn(2p), thus confirming their presence in 
the original MnPD-NPs. After the displacement reaction, the 
survey scan spectrum exhibits the characteristic peaks of C(1s), 
O(1s), N(1s), and Gd(4d), and the characteristic peaks of Mn2p 
have been eliminated. The resulting nanoparticles show a Gd 
loading of 11 wt% and a negligible amount of Mn (0.006 wt%) 
by ICP-OES measurement, consistent with the XPS data. 
Therefore, we hypothesize that the Mn(III) was replaced by 
Gd(III) due to weaker binding of Mn(III) to polydopamine 
compared with Gd(III).[15c] These GdPD-NPs were character-
ized by TEM and DLS with no change in morphology compared 
to the initial MnPD-NP species (Figure 1d and Figures S1 and 
S2 and Table S1, Supporting Information). In addition, by 
choosing templates with increased amounts of Mn(III), we can 
achieve higher Gd loadings of up to 17 wt% (Table S1, Sup-
porting Information). We also measure zeta potential of all five 
samples. All of these samples exhibited highly negative zeta 
potential value (Gd-1: −17.8 V; Gd-2: −31.3 V; Gd-3: −50.6 V; 
Gd-4: −20.7 V; Gd-5: −24.7 V), suggesting the high stability of 
these systems in aqueous solution.
In our previous study describing tunable Fe(III) loadings in 
PD-NPs via the prepolymerization chelation strategy, we found 
that antiferromagnetic coupling between Fe(III) centers low-
ered their r1 as we increased Fe(III) loadings in the particles.[12] 
We hypothesized that Gd(III) would exhibit much less antifer-
romagnetic coupling because of the poor radial extension of 
the f-orbitals. This implies that increasing the Gd(III) loading 
would not lead to the r1 losses observed for Fe(III), but rather a 
dramatic increase in per-particle relaxivity, with the only poten-
tial for diminishing returns being core-localized metal ions 
having less access to water. Therefore, we aimed to determine 
optimal loading conditions by measuring r1 as a function of 
Gd(III) loading.
The measurement of r1 and transverse water proton relaxa-
tion rates (r2) as a function of applied magnetic field for the 
five GdPD-NPs (Table 1) was undertaken to assess their T1 con-
trast enhancing ability. Nuclear magnetic relaxation dispersion 
(NMRD) allows accurate determination of the field dependence 
of r1 that arises from magnetic interactions between the metal 
centers and the solvent (Figure 2).[3b,16] The NMRD profiles are 
characteristic of slowly rotating systems with a shallow decrease 
of r1 at about 1–5 MHz and a broad and pronounced peak cen-
tered at 30–50 MHz. All five curves share similar characteristics 
across the entire frequency range, but appear offset from one 
Small 2017, 13, 1701830
Table 1. Selected relaxation parameters obtained from the analysis of NMRD profiles (298 K).










q τM  
[ns]d)
Gd-1 63.4 8.1d) 17d) 1.5 ± 0.2 3.0 1.8 ± 0.1 30
Gd-2 56.9 8.1d) 17d) 1.4 ± 0.1 3.0 1.6 ± 0.1 30
Gd-3 74.6 8.4 ± 1.1 16 ± 1 1.5 ± 0.3 3.0 2d) 30
Gd-4 52.3 8.1d) 17d) 1.4 ± 0.1 3.0 1.4 ± 0.1 30
Gd-5 35.1 8.1 ± 0.9 17 ± 1 1.2 ± 0.3 3.0 1d) 30
a)The outer-sphere component of the relaxivity was estimated using standard values for the distance of closest approach a (4 Å) and the relative diffusion coefficient of 
solute and solvent D (2.2 × 10−5 cm2 s−1); b)60 MHz; c)The parameters for electronic relaxation are used as empirical fitting parameters and do not have a real physical 
meaning for slowly tumbling nanosized systems. Low-field data, those most affected by electronic relaxation, were not included in data analysis; d)Fixed during the fit.
Figure 2. 1H NMRD profiles for Gd-i (i = 1–5). The x-axis is proton Larmor 
frequency and the y-axis is r1 value per Gd(III) ion for each sample.
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another by a scaling factor. The fact that the NMRD profiles 
exhibit a common shape but offset in this way suggests that 
the origin of the relaxivity differences must be a parameter that 
directly influences r1 without being field-dependent. Relaxivity 
scales either with the hydration number q or with the distance, 
rGdH, between the coordinated water proton and the Gd(III) 
S = 7/2 electron spin. According to data for small Gd(III) che-
lates, the rGdH values are typically found in the narrow range of 
≈3.0–3.2 Å, with no evidence of a dependence on the coordina-
tion geometry of the metal complex.[17] Therefore, it is plausible 
that the different amplitude of the five NMRD profiles reflects 
a change in the hydration state of the Gd(III) ions. Therefore, 
we first analyzed Gd-5 assuming the presence of one water 
molecule in the inner coordination sphere of Gd(III) centers 
throughout the structure, as the relaxivity values are in line 
with those of other macromolecular Gd-based systems with 
q = 1.[2a,5,18] We note that only frequencies above 3 MHz were 
analyzed, as Solomon–Bloembergen–Morgan theory is not ade-
quate to account for the data at low magnetic fields in the case 
of slowly rotating systems. The temperature dependency of r1 
at high field clearly indicates the occurrence of fast exchange 
conditions. That is, r1 is not limited by water exchange. We then 
fixed this parameter at 30 ns and performed the fit treating 
three parameters as variables, namely, the overall rotational cor-
relation time (τR), the correlation time for the transient zero-
field splitting (ZFS; τV), and the amplitude of the transient ZFS 
(Δ2). The best-fit parameters obtained for the GdPD-NPs from 
the analysis of 1H NMRD data are shown in Table 1. We con-
clude that the tight packing of Gd-centers at catecholate groups 
throughout crosslinked polymers within the NPs results in a 
rotationally restricted system at the metal centers and their che-
lates. The absence of internal rotation of the Gd-chelates leads 
to a very good fit, even at high frequencies, with a single global 
rotational correlation time of 1.2 ns. Likewise, the NMRD pro-
file of Gd-3 can be fitted by simply assuming q = 2. The other 
parameters vary only marginally reinforcing the hypothesis 
that relaxivity changes are associated with changes in the state 
of hydration of the paramagnetic centers. A q value of 2 could 
be associated with a larger number of Gd ions exposed to the 
surface and more accessible to water molecules, whereas q = 1 
might arise as an average between the Gd centers on the surface 
(q = 2) and those in the inner core of the NPs, not accessible to 
water (q = 0). The NMRD profiles of NPs Gd-4, Gd-2, and Gd-1 
were analyzed by fitting only q and τR. The best results were 
obtained with the parameters shown in Table 1, where the rota-
tional correlation time is essentially unchanged and the effec-
tive q value scales with the relaxivity, from 1.4 to 1.8.
The r1 values (1.4 T; 60 MHz) demonstrate the presence 
of facile relaxation in all five samples (Table S2, Supporting 
Information). Gd-3 has an r1 value of 75 mM−1 s−1, 20-fold 
higher than commercially used Gd-based contrast agents 
(i.e., Gd-DOTA) and superior to many previously reported 
macromolecules and nanoscale formulations (such as 
liposomes and dendritic species).[19] It is also the highest one 
among the five tested samples. Therefore 5% is the optimal 
loading conditions for achieving the highest per Gd ion 
relaxivity, which is approaching the theoretical limit. When 
increasing the Gd loading to 17% (Gd-5), the r1 value remains 
relatively high (35 mM−1 s−1). The decrease of r1 may be due 
to the larger size of Gd-5 preventing water coordination of 
paramagnetic centers within the core of the particle. The r2/r1 
ratios at various field strengths (20–70 MHz) were determined 
(Figure S5, Supporting Information) and not surprisingly, these 
ratios increase with increasing proton Larmor frequency, with 
the highest value being under 3, indicating that Gd-1–5 act as 
T1-weighted contrast agents with relatively little interference 
from T2 darkening.
Given that each particle contains many chelated Gd(III) 
ions, it is interesting to consider the “per-particle relaxivity” 
(r1p(particle)) to describe the local concentration necessary to 
achieve the desirable T1 MRI contrast under different magnetic 
fields (Figure 3).[20] Interestingly, plots of r1p(particle) and r1p(Gd(III)) 
show different trends. Whereas r1p(Gd(III)) reveals a maximum 
relaxivity for Gd-3, the plot of r1p(particle) shows that relaxivity 
increases monotonically with doping amount on a per-particle 
basis. Thus, Gd-5 exhibits the highest per-particle relaxivity, 
about five times larger than the Gd-1 at 60 MHz (Figure 3). 
These data lead to the intuitive result that highly paramagneti-
cally doped particles are superior to those doped with lower 
levels of Gd(III) ions.
To evaluate the potential utility of GdPD-NPs as T1-weighted 
contrast agents at high magnetic fields, we calculated their r1 
values and captured T1-weighted MR images using a volume 
coil with a 7-tesla (T) MRI scanner. The T1 relaxation times 
became shorter and the phantom image became brighter as 
the Gd(III) concentrations increased (Figure 4a–d), suggesting 
that the GdPD-NPs accelerated the recovery of net magnetiza-
tion. At 7 T, Gd-3 has the highest r1 value (r1 = 10.5 mM−1 s−1), 
while the other four samples exhibit only slightly lower values. 
This value is roughly four times higher than common com-
mercial contrast agents such as Gd-DOTA (r1 = 3.0 mM−1 s−1) 
and Gd-DTPA (r1 = 3.1 mM−1 s−1).[21] Additionally, the rough 
equivalence of Gd-1–5r1 values means that a significantly lower 
Gd(III) ion dosage can be used without sacrificing the contrast 
enhancement ability. The r2/r1 values (Table S3, Supporting 
Information) are larger compared with the ones at 1.4 T due to 
the enhanced T2 effect at high field. To demonstrate the poten-
tial for Gd-i to be used as contrast agents, they were incubated 
with HeLa cells and shown to provide enhanced positive con-
Small 2017, 13, 1701830
Figure 3. 1H NMRD profiles for Gd-i (i = 1–5). The x-axis is proton Larmor 
frequency and the y-axis is r1 value per nanoparticle for each sample.
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trast in T1-weighted MR images as compared to control cells 
(Figure 4). Overall, the high T1 relaxivity and low r2/r1 ratio of 
GdPD-NPs could make them suitable as low dosage, Gd-based 
contrast agents for T1-weighted MRI measurements.
A key prerequisite for in vivo imaging applications is low 
toxicity. For Gd-i to be useful, Gd(III) ions must not be sus-
ceptible to transmetallation as this would result in a release of 
potentially harmful free Gd(III) ions.[22] Thus it is important to 
examine the selectivity of these nanoparticles for Gd(III) over 
physiological metal ions, such as Ca(II) and Zn(II). We use 
Gd-3 to examine stability of Gd(III) coordination over Ca(II) 
and Zn(II) at their maximum human blood concentration 
(2.5 × 10−3 m for Ca(II) and 0.15 × 10−3 m for Zn(II)). Gd-3 was 
incubated with aqueous CaCl2 and ZnCl2 solutions for 7 d, fol-
lowed by multiple washing and centrifugation steps to remove 
free metal ions. The sample was then analyzed via ICP-OES 
to show no significant release of Gd(III) ion on this timescale 
(Figure S6, Supporting Information). The stability of Gd-3 in 
various media was also examined. We observe that the amount 
of chelated Gd(III) ion does not change significantly over 
time in water, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) and Phosphate Buffered Saline (PBS) buffer 
(Figure S7, Supporting Information). Although the cell viability 
of PD-NPs had already been confirmed,[23] the cytotoxicity 
of GdPD-NPs has not yet been evaluated. Nanoparticles with 
negatively charged surfaces often exhibit a lower cytotoxicity 
compared to those with positively charged ones.[24] We tested 
the toxicity of samples with various loadings of Gd(III) (Gd-1, 
Gd-3, Gd-4, Gd-5, and PD-NP). The results showed no obvious 
cytotoxicity after incubation with Gd-1, Gd-3, or Gd-4 at levels 
up to 125 µg mL−1 within 48, while the Gd-5 sample showed 
some cytotoxicity at high concentration (125 µg mL−1) that may 
come from the high content of Gd(III) inside the nanoparticle 
(Figure S8, Supporting Information). We recently found that 
polydopamine nanoparticles undergo a similar degradation 
pathway as natural melanosomes.[25] In addition, Gd(III) is also 
known to have high affinity to catecholate units.[26] Therefore 
we anticipate that the GdPD-NPs, upon possible degradation in 
vivo over the long term, would stay in chelated form.
In our previous work,[12] it was shown that increasing Fe(III) 
ion concentration within polydopamine nanoparticles led to 
antiferromagnetic coupling that correlated with decreases in 
MR contrast. To investigate whether Gd(III)–Gd(III) coupling 
or the formation of Gd oxide phases at high concentrations 
could be playing a role in the decrease in r1, the magnetic prop-
erties of GdPD-NPs were investigated by variable-temperature 
magnetic susceptibility measurements from 2 to 300 K under 
a 5000 Oe magnetic field (Figure S9, Supporting Information). 
Unlike in FePD-NPs, there is no appreciable deviation from 
single-ion, spin-only behavior (χMT = 7.88 emu K cm−3 mol−1) 
for the three GdPD-NP samples that were tested. This indicates 
a nearly complete lack of antiferromagnetic coupling between 
Gd(III) centers in the polydopamine systems. These data indi-
cate that the drop in per-Gd(III) relaxivity at high concentrations 
must be dependent on the lack of solvent access to core ions in 
the larger particles. In addition, the magnetic susceptibility of 
the S = 2 Mn(III) ion is much smaller than that of the S = 7/2 
Gd(III) ion (χMTMn(III), 300 K = 3 emu K mol−1 < χMTGd(III), 300 K = 
7.88 emu K mol−1). Even if some small amount of Mn(III) ions 
remains chelated, their contribution to the magnetic suscepti-
bility can be considered negligible.
In conclusion, we report a simple and scalable synthetic 
method of generating GdPD-NPs. We describe Gd PD-NPs 
as contrast agents with several potential advantages: (1) the 
nanoscale formulation and crosslinked nature of the Gd-
chelates leads to slow molecular tumbling increasing contrast; 
Small 2017, 13, 1701830
Figure 4. MRI characterization of Gd-i (i = 1–5) on a Bruker 7-T magnet. Plots of 1/T1 versus Gd(III) concentration and its corresponding image of 
a) Gd-1, b) Gd-2, c) Gd-3, d) Gd-4, and e) Gd-5. f) In vitro T1-weighted MR images of HeLa cells incubated with Gd-3 and PD-NP at different 
concentrations for 24 h.
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(2) restriction of the free rotation of the chelates extends to 
the surface bound Gd, due to the crosslinked polydopamine 
3D network; (3) the catechols in the 3D crosslinked network 
are strained, leading to the formation of unsaturated Gd-
catecholate, allowing high hydration states (q > 1). Finally, these 
factors result in our observation that the as-prepared nanopar-
ticles show significant MRI signal enhancement and the value 
of longitudinal relaxivity is as high as 75 mM−1 s −1 at 1.4 T 
and 10.5 mM−1 s−1 at 7 T for Gd-3. While the relatively large 
particle size (>100 nm) limits the use in targeting to the 
interstitial space of tissues,[27] these nanoparticles may have 
potential applications in tumor imaging due to the enhanced 
permeability and retention effect.[11b,13b,28]
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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